Fineline Cube

Follow:
14691 Articles
GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition
CompanyDrug

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million
CompanyDeals

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million

Haihe Biopharma's Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World's First Oral Paclitaxel Expands into Second Indication in China
Others

Haihe Biopharma’s Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World’s First Oral Paclitaxel Expands into Second Indication in China

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment
CompanyDeals

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA
CompanyDeals

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

FDA Approves Genentech's Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction
CompanyDrug

FDA Approves Genentech’s Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market
CompanyDrug

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market

Livzon Pharma Wins Approval for China's First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty
CompanyDrug

Livzon Pharma Wins Approval for China’s First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty

Hybio Pharmaceutical's AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss
CompanyDrug

Hybio Pharmaceutical’s AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss

Gan & Lee's Insulin Aspart Wins Ethiopian Registration – First Rapid‑Acting Insulin Analogue Approved in Africa's Second‑Most‑Populous Nation
CompanyDrug

Gan & Lee’s Insulin Aspart Wins Ethiopian Registration – First Rapid‑Acting Insulin Analogue Approved in Africa’s Second‑Most‑Populous Nation

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio
Others

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

Zhongsheng Pharma's RAY1225 Achieves 22.2% Weight Loss in Phase III REBUILDING‑2 Trial – Biweekly GLP‑1/GIP Dual Agonist Outperforms Tirzepatide Response Rates on Key Thresholds
CompanyDrug

Zhongsheng Pharma’s RAY1225 Achieves 22.2% Weight Loss in Phase III REBUILDING‑2 Trial – Biweekly GLP‑1/GIP Dual Agonist Outperforms Tirzepatide Response Rates on Key Thresholds